Halozyme Therapeutics (HALO)
| Sector: | Health Care |
| Super Investor Stats: | |
| Ownership count: | 1 |
| Ownership rank: | 665 |
| % of all portfolios: | 0.006% |
| History | Portfolio Manager | Activity ▼ | Share change | % change to portfolio | |
| Q1 2023 | |||||
| ≡ | Torray Funds | Reduce 21.53% | 6,781 | 0.05 | |
| Q4 2022 | |||||
| ≡ | Torray Funds | Reduce 4.31% | 1,418 | 0.01 | |
| Q2 2022 | |||||
| ≡ | Torray Funds | Reduce 25.19% | 9,527 | 0.08 | |
| Q4 2021 | |||||
| ≡ | Torray Funds | Reduce 23.18% | 10,819 | 0.06 | |
| Q2 2021 | |||||
| ≡ | Torray Funds | Reduce 1.05% | 488 | 0.00 | |
| ≡ | Lee Ainslie - Maverick Capital | Sell 100.00% | 2,711 | 0.00 | |
| Q1 2021 | |||||
| ≡ | Torray Funds | Reduce 1.38% | 652 | 0.00 | |
| ≡ | Lee Ainslie - Maverick Capital | Reduce 82.12% | 12,453 | 0.00 | |
| Q4 2020 | |||||
| ≡ | First Eagle Investment Management | Sell 100.00% | 483,800 | 0.04 | |
| Q3 2020 | |||||
| ≡ | Torray Funds | Reduce 0.69% | 324 | 0.00 | |
| ≡ | First Eagle Investment Management | Reduce 68.12% | 1,033,827 | 0.09 | |
| Q2 2020 | |||||
| ≡ | First Eagle Investment Management | Reduce 4.17% | 66,048 | 0.01 | |
| ≡ | Torray Funds | Reduce 9.60% | 4,999 | 0.03 | |
| Q1 2020 | |||||
| ≡ | First Eagle Investment Management | Reduce 3.23% | 52,800 | 0.00 | |
| ≡ | Bill Miller - Miller Value Partners | Sell 100.00% | 20,000 | 0.01 | |
| Q4 2019 | |||||
| ≡ | First Eagle Investment Management | Reduce 0.06% | 1,000 | 0.00 | |
| Q2 2019 | |||||
| ≡ | Torray Funds | Reduce 10.77% | 5,584 | 0.01 | |
| Q4 2018 | |||||
| ≡ | Bill Miller - Miller Value Partners | Reduce 88.24% | 150,000 | 0.08 | |
| Q3 2017 | |||||
| ≡ | Bill Miller - Miller Value Partners | Reduce 82.10% | 779,800 | 0.64 | |
| Q2 2013 | |||||
| ≡ | Thomas Russo - Gardner Russo & Quinn | Sell 100.00% | 376 | 0.00 | |
* "Hold Price" is the last known price at which an investor still held a security. It is the closing price of the security as of the portfolio date (quarter end). This value is only provided when a security is owned by at least two investors. In the case of reporting dates being different, a weighted average price is calculated.